Möchten Sie immer auf dem neuesten Stand bleiben?

VANCOUVER, British Columbia, March 23, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV)(FSE: 7JO0), a biopharmaceutical company advancing innovative cancer therapies through...

Hyderabad, March 20, 2026 (GLOBE NEWSWIRE) -- According to Mordor Intelligence’s latest report, the global DNA sequencing market is witnessing strong growth, driven by advancements in genomic...

SAN DIEGO, March 20, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of...

Proposed acquisition supports the Novartis oncology strategy in hormone receptor positive, human epidermal growth factor receptor two-negative (HR+/HER2-) breast cancer The lead asset, SNV4818,...

Pivotal Phase 2 with lasme-cel in r/r B-ALL (BALLI-01 trial) ongoing Phase 1: 83% ORR at RP2D and 100% ORR in the target Phase 2 populationIn target Phase 2 population: 100% of patients became...

-- DMR-001 on track for IND or CTA submission in mid-2026, with two clinical proof-of-concept datasets expected beginning mid-2027 -- -- Strong financial position with approximately $535 million in...

VANCOUVER, British Columbia, March 19, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary — Big money is moving back into biotech. Institutional investors have been writing some of the...

Delray Beach, FL, March 19, 2026 (GLOBE NEWSWIRE) -- The genomics market is projected to reach USD 85.09 billion by 2030 from USD 47.07 billion in 2025, registering a CAGR of 12.6% from 2025 to...

Exton, PA, March 19, 2026 (GLOBE NEWSWIRE) -- Spherix Global Insights’ Q1 2026 update of RealTime Dynamix™: Multiple Myeloma findings point to a clear inflection in treatment strategy, as physicians...

Pelareorep treatment drives coordinated immune activation and tertiary lymphoid structure formation  Translational data suggest potential to boost response to immunotherapy and targeted therapy in...